Empagliflozin preserves cardiac function and modulates metabolism in a mouse model of Duchenne muscular dystrophy

Duchenne muscular dystrophy (DMD) is a fatal genetic disorder characterized by skeletal muscle degeneration and cardiomyopathy. Effective cardiac therapies remain limited. This study investigated the therapeutic potential of the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (EMPA) in the dystrophin-deficient DBA2/J- mdx mouse model of DMD. Male mice received control chow or EMPA-containing chow (~25mg/kg/day), and cardiac function was evaluated longitudinally using four-dimensional ultrasound imaging. EMPA did not alter left ventricular mass or volume but delayed the onset of systolic dysfunction, preserving ejection fraction (EF) for 12 weeks and maintaining significantly higher EF through 24 weeks. EMPA also attenuated progressive impairments in systolic and diastolic myocardial deformation. Functional preservation was accompanied by reduced cardiomyocyte hypertrophy and reduced expression of cardiac stress genes. EMPA increased mtDNA copy number, reduced mtDNA damage, preserved the mtDNA-encoded respiratory chain protein MT-CO1, and increased myocardial ATP content, supporting improved mitochondrial integrity and myocardial energetic capacity. In addition, EMPA induced transcriptional changes consistent with enhanced fatty acid and ketone metabolism. Systemically, EMPA improved growth trajectory, preserved relative lean mass, increased skeletal muscle torque, attenuated fiber-type remodeling, and did not adversely affect renal function. Together, these findings support SGLT2 inhibitors as a promising therapeutic strategy for DMD-associated cardiomyopathy.

Authors

Institutions

Publication Details

Journal
JCI Insight
Published
2026-11-19
DOI
https://doi.org/10.1172/jci.insight.206796
Citations
1
Primary Topic
Cardiovascular Function and Risk Factors
Type
article
Field-Weighted Citation Impact
2.91

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Empagliflozin preserves cardiac function and modulates metabolism in a mouse model of Duchenne muscular dystrophy

Carol A. Witczak, Meena S. Madhur, Steven S. Welc, Akanksha Agrawal et al.
1 citations
JCI Insight
Cardiovascular Function and Risk Factors
2.91
article

Empagliflozin preserves cardiac function and modulates metabolism in a mouse model of Duchenne muscular dystrophy

Carol A. Witczak, Meena S. Madhur, Steven S. Welc, Akanksha Agrawal, Linda A. Bean, Joshua R. Huot, Li‐Fan Zeng, Craig J. Goergen, Areli Jannes S. Javier, Conner C. Earl, Larry Wayne Markham, John P. Salvas, Il‐man Kim, Mark C. Kowala, B. Zeidler, Connor R Thomas, Alyssa M. Richards, Niharika Narra, Lifan Zeng
article en
1 citations

Abstract

Duchenne muscular dystrophy (DMD) is a fatal genetic disorder characterized by skeletal muscle degeneration and cardiomyopathy. Effective cardiac therapies remain limited. This study investigated the therapeutic potential of the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (EMPA) in the dystrophin-deficient DBA2/J- mdx mouse model of DMD. Male mice received control chow or EMPA-containing chow (~25mg/kg/day), and cardiac function was evaluated longitudinally using four-dimensional ultrasound imaging. EMPA did not alter left ventricular mass or volume but delayed the onset of systolic dysfunction, preserving ejection fraction (EF) for 12 weeks and maintaining significantly higher EF through 24 weeks. EMPA also attenuated progressive impairments in systolic and diastolic myocardial deformation. Functional preservation was accompanied by reduced cardiomyocyte hypertrophy and reduced expression of cardiac stress genes. EMPA increased mtDNA copy number, reduced mtDNA damage, preserved the mtDNA-encoded respiratory chain protein MT-CO1, and increased myocardial ATP content, supporting improved mitochondrial integrity and myocardial energetic capacity. In addition, EMPA induced transcriptional changes consistent with enhanced fatty acid and ketone metabolism. Systemically, EMPA improved growth trajectory, preserved relative lean mass, increased skeletal muscle torque, attenuated fiber-type remodeling, and did not adversely affect renal function. Together, these findings support SGLT2 inhibitors as a promising therapeutic strategy for DMD-associated cardiomyopathy.

JCI Insight
Indiana University Health (US), Purdue University West Lafayette (US), Indiana University Indianapolis (US), Indiana University School of Medicine (US), Indiana University – Purdue University Indianapolis (US)
Purdue University, Riley Children's Foundation, National Institutes of Health, School of Medicine, Indiana University, National Heart, Lung, and Blood Institute, National Institute of Arthritis and Musculoskeletal and Skin Diseases
Good health and well-being
Openalex Percentile: Top 16%
Cardiovascular Function and Risk Factors
2.91
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon